Entasis Therap Drug Patent Portfolio
Entasis Therap owns 1 orange book drug protected by 4 US patents Given below is the list of Entasis Therap's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10376499 | Combination therapy for treatment of resistant bacterial infections | 17 Nov, 2035 | Active |
| US9968593 | Combination therapy for treatment of resistant bacterial infections | 17 Nov, 2035 | Active |
| US9309245 | Beta-lactamase inhibitor compounds | 02 Apr, 2033 | Active |
| US9623014 | β-lactamase inhibitor compounds | 02 Apr, 2033 | Active |
Latest Legal Activities on Entasis Therap's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Entasis Therap.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Notice of Final Determination- Ineligible | 26 Apr, 2024 | US9309245 |
| Notice of Final Determination- Ineligible | 26 Apr, 2024 | US10376499 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US9309245 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US10376499 |
| Initial letter Re: PTE Application to regulating agency | 17 Jan, 2024 | US9309245 |
| Initial letter Re: PTE Application to regulating agency | 17 Jan, 2024 | US10376499 |
| Requirement for information sent under 37 CFR 1.750 | 17 Nov, 2023 | US9309245 |
| Requirement for information sent under 37 CFR 1.750 | 17 Nov, 2023 | US10376499 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Oct, 2023 | US9309245 |
| Requirement for information sent under 37 CFR 1.750 | 09 Aug, 2023 | US9309245 |
| Requirement for information sent under 37 CFR 1.750 | 09 Aug, 2023 | US10376499 |
| Patent Term Extension Application under 35 USC 156 Filed | 24 Jul, 2023 | US10376499 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Feb, 2023 | US10376499 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Nov, 2021 | US9968593 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Oct, 2020 | US9623014 |
Entasis Therap's Family Patents
Entasis Therap Drug List
Given below is the complete list of Entasis Therap's drugs and the patents protecting them.
1. Xacduro (copackaged)
Xacduro (copackaged) is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10376499 | Combination therapy for treatment of resistant bacterial infections |
17 Nov, 2035
(11 years from now)
| Active |
| US9968593 | Combination therapy for treatment of resistant bacterial infections |
17 Nov, 2035
(11 years from now)
| Active |
| US9309245 | Beta-lactamase inhibitor compounds |
02 Apr, 2033
(8 years from now)
| Active |
| US9623014 | β-lactamase inhibitor compounds |
02 Apr, 2033
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xacduro (copackaged)'s drug page